AstraZeneca demonstrated strong financial performance and significant pipeline advancements, particularly in oncology and biopharmaceuticals. However, challenges remain with Medicare Part D redesign, biosimilar competition, and specific pipeline setbacks.

Company Guidance -

Q3 2025

During the AstraZeneca H1 and Q2 2025 conference call, the company provided an optimistic financial outlook, highlighting an 11% revenue growth in the first half of the year, driven by strong demand for innovative medicines. Core EPS rose by 17%, showcasing the company's commitment to pipeline investment and operational efficiency. AstraZeneca reported 19 regulatory approvals in key regions and 12 positive Phase III trial results, including five new molecular entities. The oncology segment saw a 16% revenue increase, while biopharmaceuticals grew by 10%. The company also reiterated its 2030 revenue target of $80 billion, emphasizing its diverse pipeline and transformative technologies poised to sustain long-term growth. Despite the challenges, AstraZeneca remains confident, supported by a strong cash flow, significant investments in R&D, and strategic global expansions.

Solid Financial Growth

Total revenue increased by 11%, and core EPS grew 17% in the first half of 2025, reflecting strong demand for AstraZeneca's innovative medicines.

Pipeline Success

AstraZeneca announced 12 positive Phase III trial results this year, including the first pivotal data for 5 new molecular entities, with a potential to generate over $10 billion in peak year revenue.

Oncology Revenue Surge

Oncology total revenues grew 16% to $12 billion in the first half, driven by strong double-digit growth across the U.S., Europe, and emerging markets.

Enhertu Growth

Enhertu total revenues grew 42% in the second quarter, reflecting sustained market leadership in HER2-positive and HER2 low metastatic breast cancer.

Biopharmaceuticals Revenue Growth

Biopharmaceuticals delivered strong performance with 10% growth, reaching total revenue of $11.2 billion, with R&I and CVRM segments showing robust increases.

Baxdrostat Phase III Success

Baxdrostat showed significant promise in the BaxHTN Phase III trial for uncontrolled resistant hypertension, meeting primary and secondary endpoints with a favorable safety profile.

AstraZeneca (AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	1.14 / -	1.04	―	―	―
Jul 29, 2025	2025 (Q2)	1.07 / 1.08	0.99	9.60% (+0.09)
Apr 29, 2025	2025 (Q1)	1.12 / 1.25	1.03	20.87% (+0.22)
Feb 06, 2025	2024 (Q4)	1.03 / 1.04	0.725	44.14% (+0.32)
Nov 12, 2024	2024 (Q3)	1.02 / 1.04	0.865	20.23% (+0.18)
Jul 25, 2024	2024 (Q2)	0.98 / 0.99	1.075	-7.91% (-0.08)
Apr 25, 2024	2024 (Q1)	0.96 / 1.03	0.96	7.29% (+0.07)
Feb 08, 2024	2023 (Q4)	0.73 / 0.72	0.69	5.07% (+0.04)
Nov 09, 2023	2023 (Q3)	0.84 / 0.86	0.835	3.59% (+0.03)
Jul 28, 2023	2023 (Q2)	0.99 / 1.07	0.86	25.00% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$71.34	$73.48	+3.00%
Apr 29, 2025	$69.46	$71.22	+2.53%
Feb 06, 2025	$69.48	$70.88	+2.01%
Nov 12, 2024	$63.46	$63.85	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.